NO310236B1 - Nye 2,3-diokso-1,2,3,4-tetrahydro-quinoksalinylderivater og farmasöytisk sammensetning omfattende samme - Google Patents

Nye 2,3-diokso-1,2,3,4-tetrahydro-quinoksalinylderivater og farmasöytisk sammensetning omfattende samme Download PDF

Info

Publication number
NO310236B1
NO310236B1 NO19980814A NO980814A NO310236B1 NO 310236 B1 NO310236 B1 NO 310236B1 NO 19980814 A NO19980814 A NO 19980814A NO 980814 A NO980814 A NO 980814A NO 310236 B1 NO310236 B1 NO 310236B1
Authority
NO
Norway
Prior art keywords
dioxo
tetrahydroquinoxalin
ylmethyl
nitro
acid
Prior art date
Application number
NO19980814A
Other languages
English (en)
Norwegian (no)
Other versions
NO980814L (no
NO980814D0 (no
Inventor
Pierre Acklin
Hans Allgeier
Yves Auberson
Michel Biollaz
Robert Moretti
Silvio Ofner
Siem Jacob Veenstra
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO980814D0 publication Critical patent/NO980814D0/no
Publication of NO980814L publication Critical patent/NO980814L/no
Publication of NO310236B1 publication Critical patent/NO310236B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • C07F9/650994—Six-membered rings having the nitrogen atoms in the positions 1 and 4 condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO19980814A 1995-08-31 1998-02-26 Nye 2,3-diokso-1,2,3,4-tetrahydro-quinoksalinylderivater og farmasöytisk sammensetning omfattende samme NO310236B1 (no)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CH247995 1995-08-31
CH273495 1995-09-27
CH274795 1995-09-28
CH121396 1996-05-10
CH163096 1996-06-28
PCT/EP1996/003644 WO1997008155A1 (en) 1995-08-31 1996-08-19 Novel 2,3-dioxo-1,2,3,4-tetrahydro-quinoyxalinyl derivatives

Publications (3)

Publication Number Publication Date
NO980814D0 NO980814D0 (no) 1998-02-26
NO980814L NO980814L (no) 1998-04-21
NO310236B1 true NO310236B1 (no) 2001-06-11

Family

ID=27508939

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19980814A NO310236B1 (no) 1995-08-31 1998-02-26 Nye 2,3-diokso-1,2,3,4-tetrahydro-quinoksalinylderivater og farmasöytisk sammensetning omfattende samme

Country Status (25)

Country Link
US (1) US6080743A (cs)
EP (1) EP0853617B1 (cs)
JP (1) JP3159711B2 (cs)
KR (1) KR100462337B1 (cs)
CN (1) CN1137886C (cs)
AR (1) AR005229A1 (cs)
AT (1) ATE260902T1 (cs)
AU (1) AU705871B2 (cs)
BR (1) BRPI9603626B8 (cs)
CA (1) CA2227851C (cs)
CZ (1) CZ56298A3 (cs)
DE (1) DE69631774T2 (cs)
DK (1) DK0853617T3 (cs)
ES (1) ES2217324T3 (cs)
HU (1) HUP9801676A3 (cs)
IL (1) IL122987A (cs)
MY (1) MY132385A (cs)
NO (1) NO310236B1 (cs)
NZ (1) NZ316497A (cs)
PL (1) PL189637B1 (cs)
PT (1) PT853617E (cs)
SI (1) SI0853617T1 (cs)
SK (1) SK25298A3 (cs)
TR (1) TR199800349T2 (cs)
WO (1) WO1997008155A1 (cs)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6191134B1 (en) * 1996-06-05 2001-02-20 Warner-Lambert Company Amide derivatives of substituted quinoxaline 2, 3-diones as glutamate receptor antagonists
CZ141399A3 (cs) * 1996-10-24 1999-07-14 Novartis Ag Substituované aminoalkanfosfonové kyseliny, způsob jejich přípravy a farmaceutické prostředky, které je obsahují
ZA9710553B (en) * 1996-11-25 1998-06-10 Warner Lambert Co Urea and thiourea derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists.
GB9702194D0 (en) 1997-02-04 1997-03-26 Lilly Co Eli Sulphonide derivatives
US6172065B1 (en) 1997-03-04 2001-01-09 Warner-Lambert Company Urea and thiourea derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
US6340758B1 (en) 1997-05-16 2002-01-22 Warner-Lambert Company Conformationally semi-constrained quinoxaline 2,3-diones as neuroprotective agents
US6096744A (en) * 1998-05-04 2000-08-01 Warner-Lambert Company Sulfonamide derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
US7361666B2 (en) 1999-05-25 2008-04-22 Sepracor, Inc. Heterocyclic analgesic compounds and methods of use thereof
US6635661B2 (en) 2000-05-25 2003-10-21 Sepracor Inc. Heterocyclic analgesic compounds and methods of use thereof
US6645980B1 (en) 2000-05-25 2003-11-11 Sepracor Inc. Heterocyclic analgesic compounds and methods of use thereof
US6677332B1 (en) 1999-05-25 2004-01-13 Sepracor, Inc. Heterocyclic analgesic compounds and methods of use thereof
CA2440284A1 (en) * 2001-03-08 2002-09-19 Emory University Ph-dependent nmda receptor antagonists
TW200403066A (en) * 2002-04-30 2004-03-01 Novartis Ag New uses of substituted aminoalkanephosphonic acids
US7524837B2 (en) * 2003-05-12 2009-04-28 Janssen Pharmaceutica N.V. Benzotriazapinone salts and methods for using same
GB0310868D0 (en) * 2003-05-12 2003-06-18 Novartis Ag Organic compounds
KR20060111466A (ko) * 2003-09-30 2006-10-27 얀센 파마슈티카 엔.브이. 퀴녹살린 화합물
US20060020029A1 (en) * 2004-07-02 2006-01-26 Shimasaki Craig D Pharmaceutical compositions from ethnobotanicals
UA95788C2 (en) * 2005-12-15 2011-09-12 Ф. Хоффманн-Ля Рош Аг Fused pyrrole derivatives
EA201070077A1 (ru) 2007-06-29 2010-08-30 Эмори Юниверсити Антагонисты nmda-рецепторов с нейропротективным действием
US20130053381A1 (en) * 2010-05-20 2013-02-28 Novartis Ag 2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl-sulfonamide derivatives
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
JO3225B1 (ar) * 2012-11-27 2018-03-08 Lilly Co Eli 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8
CN103435561B (zh) * 2013-08-19 2016-08-10 上海交通大学 一种新型d-氨基酸氧化酶抑制剂及其制备和应用
MX2019008918A (es) * 2017-01-27 2020-02-19 Genfit Derivados de n-{[2-(piperidin-1-il)(fenil)metil}-2-(3-oxo-3,4-dihi dro-2h-1,4-benzoxazin-7-il)acetamida y compuestos relacionados como moduladores de ror-gamma para tratar enfermedades autoinmunes.
BR112019026449A2 (pt) 2017-06-12 2020-08-11 Glytech Llc. composição e método para tratamento de depressão e psicose em humanos

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4156734A (en) 1976-02-13 1979-05-29 Merck & Co., Inc. Antihypertensive compositions containing an aryl-substituted alanine azo and an arylhydrazino-propionic acid
CA2002864C (en) * 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
JPH04506967A (ja) * 1989-07-27 1992-12-03 ジー．ディー．サール　アンド　カンパニー 高血圧症治療用腎選択性生成物
US5631373A (en) * 1993-11-05 1997-05-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones
GB9418443D0 (en) * 1994-09-13 1994-11-02 Pfizer Ltd Therapeutic agents
GB9419318D0 (en) * 1994-09-24 1994-11-09 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
ES2217324T3 (es) 2004-11-01
MY132385A (en) 2007-10-31
HUP9801676A3 (en) 1999-04-28
KR100462337B1 (ko) 2005-02-28
IL122987A (en) 2001-08-08
SI0853617T1 (en) 2004-08-31
WO1997008155A1 (en) 1997-03-06
AU6874296A (en) 1997-03-19
BRPI9603626B8 (pt) 2021-07-06
HK1010196A1 (en) 1999-06-17
NZ316497A (en) 2000-01-28
DE69631774T2 (de) 2005-01-13
DE69631774D1 (de) 2004-04-08
IL122987A0 (en) 1998-08-16
KR19990044275A (ko) 1999-06-25
NO980814L (no) 1998-04-21
PL324992A1 (en) 1998-07-06
CA2227851C (en) 2009-01-06
CN1193968A (zh) 1998-09-23
AU705871B2 (en) 1999-06-03
JP3159711B2 (ja) 2001-04-23
US6080743A (en) 2000-06-27
EP0853617B1 (en) 2004-03-03
PT853617E (pt) 2004-06-30
CN1137886C (zh) 2004-02-11
BRPI9603626B1 (pt) 2016-08-23
NO980814D0 (no) 1998-02-26
MX9801643A (es) 1998-08-30
DK0853617T3 (da) 2004-07-05
CZ56298A3 (cs) 1998-06-17
EP0853617A1 (en) 1998-07-22
TR199800349T2 (xx) 1998-09-21
HUP9801676A2 (hu) 1999-03-29
PL189637B1 (pl) 2005-09-30
JPH11511444A (ja) 1999-10-05
ATE260902T1 (de) 2004-03-15
CA2227851A1 (en) 1997-03-06
AR005229A1 (es) 1999-04-28
SK25298A3 (en) 1998-09-09

Similar Documents

Publication Publication Date Title
NO310236B1 (no) Nye 2,3-diokso-1,2,3,4-tetrahydro-quinoksalinylderivater og farmasöytisk sammensetning omfattende samme
US5576318A (en) Benzimidazolone derivatives
NZ204996A (en) 4-amino-6,7-dimethoxyquinoline derivatives
JP3590589B2 (ja) Ｃｎｓ障害の処置のための１−アレーンスルホニル−２−アリール−ピロリジン及びピペリジン誘導体
IE891240L (en) 1,3-Disubstituted pyrrolidines
HUP0202001A2 (hu) DDP-IV gátló hatású azabiciklooktán- és nonánszármazékok
JPH05255258A (ja) 置換されたビフエニルピリドン類
JPH05140149A (ja) 縮合複素環誘導体
JPH046684B2 (cs)
BG100040A (bg) Индолови производни като 5-нт1а и/или 5-нт2 лиганди
HUT59128A (en) Process for producing cck antagonist 3-aryl-4-(3h)-quinazolinones and pharmaceutical compositions comprising same
NZ289498A (en) Piperidinylpiperazine derivatives such as various piperidinylpiperazinylacetylphenoxy acetic acid derivatives, pharmaceutical compositions
NZ211425A (en) Diazepines and pharmaceutical compositions
JP4108123B2 (ja) Ｎｍｄａアンタゴニストとしてのテトラヒドロキノリン
CA2841897A1 (en) Novel compound having parp inhibitory activity
CZ2003893A3 (cs) Benzodiazepinové deriváty
JPH0841027A (ja) ３−ヘテロ脂肪−及び３−ヘテロ（アリール）脂肪−２（１ｈ）−キノロン誘導体
JPH01128970A (ja) 新規複素環誘導体
JP2010540503A (ja) Ｇタンパク質インヒビターとしてのピラゾロ−ピラジン誘導体
MXPA98001643A (en) Derivatives of 2, 3-dioxo-1,2,3,4-tetrahidro-quinoxalinilo novedo
EP0840609B1 (en) Use of unsubstituted and substituted n-(pyrrol-1-yl)pyridinamines as anticonvulsant agents
JPH0525140A (ja) ベンズイミダゾール誘導体
JP2003277263A (ja) 医薬組成物
KR101122376B1 (ko) 신규의 5,6-다이메틸피리미딘 유도체 및 그의 제조방법
IL151521A (en) Use of unsubstituted and substituted n-(pyrrol-1-yl) pyridinamines in the preparation of anticonvulsant pharmaceutical compositions, and pharmaceutical compositions comprising them